Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
great comparison... Aspirin and MANF thanks..
Aspirin works on a fever... lots of money made on Aspirin..
admiting MANF works short term is good enough for me and the people suffering from PD...
GL2U stay out of it... sell sh-rt all you want
and have a nice day
Regenerating dopamine producing brain cells is disease modifying
AMBS.
Until now
They cant grab it. Its owned by Doc Commisiong.
When MANF gets funded what are you going to say?
What did you edit out if their reply?
Yes its getting a lot of attention and fast
ONCI.
Holding 2M shares.ONCI. Looking to add more this is prime for a run.
GL2ALL
This bodes well for the work AMBS and Banyan Biomarkers are doing together with funding help ($26 Million) from our government.
TBI, CTE : Testing MANF on TBI rat models and so far results are positive.
Nice DD. that is exactly what those notes mean. On AMBS LymPro white paper
Very Nice DD on AMBS LymPro
AMBS Gerald had some business he was dealing with in Maryland not too long ago.. check out which division of BD is in Maryland
BD Diagnostics
Diagnostic Systems
7 Loveton Circle
Sparks, MD 21152 USA
http://www.bd.com/ds/aboutUs/officeLocations.asp
maybe AMBS removed it after I sent them an email asking them about BD Becton Dickinson and another few Initials I found in the Charts LOL
we shall see.
GL2ALL
with 7.7 Billion in Sales I am sure they can get some lose change together if they wanted to ... check again
Read the chart is pretty self explanatory . they will Generate Sales beginning this 3rd Quarter .. selling the Kit as a RUO test research use only test and as a CDx( Companion Diagnostic Test ) to Pharma who are developing Alzheimer drug candidates, Revenue is around the corner. and it should not be Chump change either.
The IVD US & EU test kits are further down the road as stated on the Chart...that is unless they get a nice JV to help expedite the development plan..
I expect a JV.. we all shall see.
Just what is says... European Sales of its In Vitro Diagnostics Kit
look up the Chart its on page 21 of AMBS Lympro White Paper.
IMO this is the GLP Lab AMBS Is using its mentioned by Initials on the Lympro White Paper http://www.bd.com/
BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. BD is headquartered in the United States and has offices in more than 50 countries worldwide.
this is a very big company... and I would not be surprised if that company it self has JV on its mind..
[URL=http://imageshack.us/photo/my-images/708/chartlym.png/][/URL]
Uploaded with [URL=http://imageshack.us]ImageShack.us[/URL]
Its only a bother when you ask a question that you know the answer to.
If you didn;t know the answer then I apologize for being a D---
not until Mid May can they convert the shares.. and only once they reach .10 and you should not ask ignorant questions
it was April 12th its in the 8k's
http://ir.stockpr.com/amarantus/all-sec-filings#document-7434-0001144204-13-021468
Revenue can come as early as this 3rd Quarter as stated on the Chart on page 21 of AMBS's Lympro White Paper
[URL=http://imageshack.us/photo/my-images/845/chartlym.png/][/URL]
Uploaded with [URL=http://imageshack.us]ImageShack.us[/URL]
They will sell this test to Alzheimer Drug research companies for (RUO) Research use only and to companies that can use this as (CDx) (Companion Diagnostic for their Drug candidate)
and IMO BD Becton, Dickinson is the GLP lab they are using.. and will be the ones handling the production of the lab tests for sale now and in the future (Hopefull as they state in CHart).
www.bd.com/
Read this article..pertaining to PATENT CASE and whoever else holds patents like AMBS.... and do not forget that MONEY makes the world go round
http://www.bloomberg.com/news/2013-04-15/u-s-supreme-court-justices-seek-compromise-in-gene-patent-case.html
I was banned from posting ....I was a little too blunt to a biased AMBS Mod on here
I'm still holding my shares.. I have more than i did 2 weeks ago
AMBS
Looks like a lot of new eyes on AMBS
GL2ALL
$$$$$ AMBS $$$$$
Excellent Work.. Its appreciated
$$$$AMBS$$$$
High Court Justices Seek Compromise in Gene-Patent Case
AMBS and others Holding similar Patents have Justices on their side..
Money Talks in this world.... Justices are being swayed by.... Cough...$$$$$$$$$$$$$$$ read this
http://www.bloomberg.com/news/2013-04-15/u-s-supreme-court-justices-seek-compromise-in-gene-patent-case.html
And lets not say this lightly: AMBS already won its Patent Challenge case for MANF in Europe, even though its over seas the precedent is set, makes it harder for anyone else to try to challenge the patent.... face it, if anyone wants a piece of MANF they have to go through AMBS which = more $$$$$$
GL2ALL
AMBS 8K shows : Continued MANF development for the treatment of PD is warranted based on the results of this present study, the known mechanism of action and published literature.
My Speculation is Validation was requested by JV Partner / Or Buyout Candidate... We shall soon find out..
http://ir.stockpr.com/amarantus/all-sec-filings#document-7384-0001144204-13-020765
GL2ALL
AMBS
Smokem Remember a while back you emailed AMBS CEO Gerald about retesting the data from that original Presentation.. and he said no testing was needed and that Academia would do any further testing. IMO this Swiss Lab validation was requested by their Partner in waiting and this was needed to Close the Deal.... We shall wait and see..
GL2ALL
AMBS!!!!!!!
Speculation, but AMBS CEO Gerald might be acquiring or Partnering with http://nsgene.dk/NsGene-420.aspx for the delivery method of MANF.
Why do you ask?
1. Gerald is following them on Linkedin.
2. - NsGene has developed a superior biodelivery device to deliver biologics across the blood brain barrier
Speculation, but AMBS CEO Gerald might be acquiring or Partnering with http://nsgene.dk/NsGene-420.aspx for the delivery method of MANF.
Why do you ask?
1. Gerald is following them on Linkedin.
2. - NsGene has developed a superior biodelivery device to deliver biologics across the blood brain barrier
AMBS's Dr. Joseph Rubinfeld did not invent Amoxicillin... and we all still have infections because we all have been taking placebos for over 25 Years
AMBS - Dr. Owen Garrick is unqualified....
Corporate Advisor
Dr. Garrick joins Amarantus with over 20 years of pharmaceutical and biotechnology experience. He currently serves as the Chief Operating Officer at Bridge Clinical Research and is President of the American Medical Association Foundation. Prior to that, he was Director of Corporate Strategy and Business Development at McKesson Corporation. Dr. Garrick was Executive Director and Co-Head of Mergers & Acquisitions at Novartis Pharmaceuticals where he oversaw company acquisitions, hybrid equity/license rights deals, mature product divestments and venture investments in biotechnology companies. Prior to Novartis, Dr. Garrick was an associate at Goldman Sachs in New York. Dr. Garrick received his MD from Yale School of Medicine and earned his MBA from Wharton School of Business. He holds an AB from Princeton University, where he has served on the national fund raising board. Im being sarcastic btw
NEWS OUT !! AMBS
News for 'AMBS' - (Amarantus Outlines LymPro Alzheimer's Diagnostic Development Strategy)
SUNNYVALE, Calif., Apr 08, 2013 (BUSINESS WIRE) -- Amarantus BioScience
Holdings, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing
treatments and diagnostics for diseases associated with neurodegeneration and
apoptosis, today announced a development timeline for its LymPro Blood Test for
Alzheimer's disease
("LymPro"). LymPro is
designed to diagnose Alzheimer's disease by
identifying immune-based biomarkers in the blood of
Alzheimer's patients, allowing physicians to
definitively differentiate Alzheimer's disease from
other forms of dementia, a key unmet medical need in the management of
Alzheimer's patients. Human clinical studies for
LymPro with over 160 patients have been completed to date, showing high
sensitivity and specificity for Alzheimer's disease
diagnosis.
"The LymPro assay represents a blood-based peripheral
means to assess the integrity of the regulatory function of the cellular
machinery within the Central Nervous System," said
Amarantus corporate advisor Adam J. Simon, Ph.D.
"Although we all experience various triggers and
assaults on our brain as we age, why do some people succumb to
Alzheimer's while others show cognitive resilience?
The LymPro test can potentially tell us who is susceptible to abnormal
cell-cycle re-entry and who has sufficiently strong regulatory function in their
neurons to arrest cell-cycle re-entry due to triggers such as age, diet, viral
infection, stress, or brain injury that could eventually lead to
Alzheimer's disease."
After establishing the analytical performance of the assay in an outsourced GLP
laboratory, Amarantus plans to conduct a small clinical performance study at an
independent laboratory in the second quarter of 2013 to verify the previously
published findings. During the third quarter of 2013, the Company expects to
initiate a pivotal diagnostic accuracy study (Phase 2) at the same independent
laboratory to generate sufficient data to validate the clinical performance
(sensitivity / specificity) that would support a CLIA launch, with data
available in the first half of 2014. As part of that pivotal study, LymPro will
be evaluated as an "aid to the diagnosis of
Alzheimer's disease." The
Company intends to initiate commercial worldwide sales following assessment of
the validation study data. Thereafter, the Company intends to gain U.S.
clearance or approval for the test through the Food and Drug
Administration's de-novo Pre-market notification
510(k) or Premarket Approval (PMA) process, which would represent a 3-month to
2-year process. Ultimately, the Company believes LymPro could be approved by the
FDA as a companion diagnostic product in combination with one or more
therapeutic products.
"We are excited with the progress and upcoming
activities related to our LymPro Alzheimer's test,
which addresses a market opportunity in excess of $500 million
annually," said Gerald E. Commissiong, President and
Chief Executive Officer of Amarantus. "The FDA has
stated the importance of identifying Alzheimer's at
the earliest stage, as that is where new treatments appear to have the greatest
benefit to patients. We believe LymPro fits well within this overall strategy
and will likely have the dual benefit of improving overall diagnosis paradigms
and accuracy, while also potentially reducing overall healthcare costs if
combined with an appropriate therapeutic product as a companion
diagnostic."
The field of diagnostics for Alzheimer's disease has
been significantly bolstered in recent months with FDA guidance for drug
developers to target experimental therapies of
Alzheimer's disease towards earlier-stage patients,
as well as guidance reducing the burden of proof for drug developers to gain an
approval. In 2010 Eli Lilly & Co. acquired
Alzheimer's diagnostic developer Avid
Radiopharmaceuticals for $800 million, including $300 million up-front,
following Avid's application for marketing approval
to the FDA for florbetapir, a chemical agent used in the diagnosis of
Alzheimer's disease during a PET imaging process.
Amarantus believes that LymPro may have certain advantages over florbetapir,
including the likely cost-effectiveness of LymPro as a simple blood test in
comparison to more expensive neuro imaging techniques.
About Amarantus
Amarantus is a development-stage biotechnology company founded in January 2008.
The Company is focused on developing unique products and proprietary
technologies for the potential treatment and/or diagnosis of Parkinson's
disease, Traumatic Brain Injury, Ischemic Heart Disease and other human
diseases. The Company owns the intellectual property rights to
Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing
MANF-based products as treatments for neurological disorders where there is a
significant unmet medical need. The Company also is a Founding Member of the
Coalition for Concussion Treatment (#C4CT), a movement initiated in
collaboration with Brewer Sports International seeking to raise awareness of new
treatments in development for concussions and related nervous-system disorders.
For further information please visit www.Amarantus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements include, but
are not limited to, statements about the possible progress of the MANF
technology in testing for Parkinson's disease,
statements about expectations, plans and prospects of the development of
Amarantus' diagnostic product candidates for
Alzheimer's and
Parkinson's disease, and the potential market size
for the LymPro test for Alzheimer's disease. These
forward-looking statements are subject to a number of risks, uncertainties and
assumptions, including the risks associated with development of therapeutic drug
candidates, as well as the risks, uncertainties and assumptions relating to the
development of Amarantus' new product candidates, including those identified
under "Risk Factors" in Amarantus' most recently filed Annual Report on Form
10-K and Quarterly Report on Form 10-Q and in other filings Amarantus
periodically makes with the SEC. Actual results may differ materially from those
contemplated by these forward-looking statements Amarantus does not undertake to
update any of these forward-looking statements to reflect a change in its views
or events or circumstances that occur after the date of this presentation.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20130408005612r1&sid=cmtx4&distro=nx
SOURCE: Amarantus BioScience Holdings, Inc.
CONTACT:
Investor/Media Contact
LHA
Don Markley, Senior Vice President
310.691.7100
dmarkley@lhai.com
Copyright Business Wire 2013
-0-
NEWS OUT !! AMBS
News for 'AMBS' - (Amarantus Outlines LymPro Alzheimer's Diagnostic Development Strategy)
SUNNYVALE, Calif., Apr 08, 2013 (BUSINESS WIRE) -- Amarantus BioScience
Holdings, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing
treatments and diagnostics for diseases associated with neurodegeneration and
apoptosis, today announced a development timeline for its LymPro Blood Test for
Alzheimer's disease
("LymPro"). LymPro is
designed to diagnose Alzheimer's disease by
identifying immune-based biomarkers in the blood of
Alzheimer's patients, allowing physicians to
definitively differentiate Alzheimer's disease from
other forms of dementia, a key unmet medical need in the management of
Alzheimer's patients. Human clinical studies for
LymPro with over 160 patients have been completed to date, showing high
sensitivity and specificity for Alzheimer's disease
diagnosis.
"The LymPro assay represents a blood-based peripheral
means to assess the integrity of the regulatory function of the cellular
machinery within the Central Nervous System," said
Amarantus corporate advisor Adam J. Simon, Ph.D.
"Although we all experience various triggers and
assaults on our brain as we age, why do some people succumb to
Alzheimer's while others show cognitive resilience?
The LymPro test can potentially tell us who is susceptible to abnormal
cell-cycle re-entry and who has sufficiently strong regulatory function in their
neurons to arrest cell-cycle re-entry due to triggers such as age, diet, viral
infection, stress, or brain injury that could eventually lead to
Alzheimer's disease."
After establishing the analytical performance of the assay in an outsourced GLP
laboratory, Amarantus plans to conduct a small clinical performance study at an
independent laboratory in the second quarter of 2013 to verify the previously
published findings. During the third quarter of 2013, the Company expects to
initiate a pivotal diagnostic accuracy study (Phase 2) at the same independent
laboratory to generate sufficient data to validate the clinical performance
(sensitivity / specificity) that would support a CLIA launch, with data
available in the first half of 2014. As part of that pivotal study, LymPro will
be evaluated as an "aid to the diagnosis of
Alzheimer's disease." The
Company intends to initiate commercial worldwide sales following assessment of
the validation study data. Thereafter, the Company intends to gain U.S.
clearance or approval for the test through the Food and Drug
Administration's de-novo Pre-market notification
510(k) or Premarket Approval (PMA) process, which would represent a 3-month to
2-year process. Ultimately, the Company believes LymPro could be approved by the
FDA as a companion diagnostic product in combination with one or more
therapeutic products.
"We are excited with the progress and upcoming
activities related to our LymPro Alzheimer's test,
which addresses a market opportunity in excess of $500 million
annually," said Gerald E. Commissiong, President and
Chief Executive Officer of Amarantus. "The FDA has
stated the importance of identifying Alzheimer's at
the earliest stage, as that is where new treatments appear to have the greatest
benefit to patients. We believe LymPro fits well within this overall strategy
and will likely have the dual benefit of improving overall diagnosis paradigms
and accuracy, while also potentially reducing overall healthcare costs if
combined with an appropriate therapeutic product as a companion
diagnostic."
The field of diagnostics for Alzheimer's disease has
been significantly bolstered in recent months with FDA guidance for drug
developers to target experimental therapies of
Alzheimer's disease towards earlier-stage patients,
as well as guidance reducing the burden of proof for drug developers to gain an
approval. In 2010 Eli Lilly & Co. acquired
Alzheimer's diagnostic developer Avid
Radiopharmaceuticals for $800 million, including $300 million up-front,
following Avid's application for marketing approval
to the FDA for florbetapir, a chemical agent used in the diagnosis of
Alzheimer's disease during a PET imaging process.
Amarantus believes that LymPro may have certain advantages over florbetapir,
including the likely cost-effectiveness of LymPro as a simple blood test in
comparison to more expensive neuro imaging techniques.
About Amarantus
Amarantus is a development-stage biotechnology company founded in January 2008.
The Company is focused on developing unique products and proprietary
technologies for the potential treatment and/or diagnosis of Parkinson's
disease, Traumatic Brain Injury, Ischemic Heart Disease and other human
diseases. The Company owns the intellectual property rights to
Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing
MANF-based products as treatments for neurological disorders where there is a
significant unmet medical need. The Company also is a Founding Member of the
Coalition for Concussion Treatment (#C4CT), a movement initiated in
collaboration with Brewer Sports International seeking to raise awareness of new
treatments in development for concussions and related nervous-system disorders.
For further information please visit www.Amarantus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements include, but
are not limited to, statements about the possible progress of the MANF
technology in testing for Parkinson's disease,
statements about expectations, plans and prospects of the development of
Amarantus' diagnostic product candidates for
Alzheimer's and
Parkinson's disease, and the potential market size
for the LymPro test for Alzheimer's disease. These
forward-looking statements are subject to a number of risks, uncertainties and
assumptions, including the risks associated with development of therapeutic drug
candidates, as well as the risks, uncertainties and assumptions relating to the
development of Amarantus' new product candidates, including those identified
under "Risk Factors" in Amarantus' most recently filed Annual Report on Form
10-K and Quarterly Report on Form 10-Q and in other filings Amarantus
periodically makes with the SEC. Actual results may differ materially from those
contemplated by these forward-looking statements Amarantus does not undertake to
update any of these forward-looking statements to reflect a change in its views
or events or circumstances that occur after the date of this presentation.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20130408005612r1&sid=cmtx4&distro=nx
SOURCE: Amarantus BioScience Holdings, Inc.
CONTACT:
Investor/Media Contact
LHA
Don Markley, Senior Vice President
310.691.7100
dmarkley@lhai.com
Copyright Business Wire 2013
-0-
Stocks-New Trends Developing: Amarantus Bioscience Inc. (OTC: AMBS), bebe stores, inc. (NASDAQ:BEBE), Forest Oil Corporation (NYSE:FST)
http://www.nismagazine.com/stocks-with-new-trends-developing-amarantus-bioscience-inc-otc-ambs-bebe-stores-inc-nasdaqbebe-forest-oil-corporation-nysefst/123807/
$AMBS $800 Million Revenue Generating Potential coming into the picture fast and furiously ..
Get in or add more now..
Dr. Simon is a world-renowned expert in working with Alzheimer's disease biomarkers, and also has significant expertise in the development of in-vitro diagnostics;
http://seekingalpha.com/instablog/200555-qualitystocks/1713571-dr-adam-j-simon-joins-amarantus-bioscience-inc-ambs-board-of-advisors
thanks for the good advice...will listen to it GL2U
AMBS continues to rise this week, Alerted last week here at .06
Expecting new positive news on a JV to advance Diagnostic Blood Tests to Market with a potential $800 Million per year revenue Stream.
GL2ALL
Zoom